The design and development of 2-aryl-2-hydroxy ethylamine substituted 1H,7H-pyrido[1,2,3-de]quinoxaline-6-carboxamides as inhibitors of human cytomegalovirus polymerase

  • Bioorg Med Chem Lett. 2010 Mar 15;20(6):1994-2000. doi: 10.1016/j.bmcl.2010.01.094.
Steven P Tanis  1 ,  Joseph W Strohbach ,  Timothy T Parker ,  Malcom W Moon ,  Suvit Thaisrivongs ,  William R Perrault ,  Todd A Hopkins ,  Mary L Knechtel ,  Nancee L Oien ,  Janet L Wieber ,  Kevin J Stephanski ,  Michael W Wathen
Affiliations
  • 1. Global Research and Development, Pfizer Inc., San Diego, CA 92121, USA. [email protected]
PMID: 20167488 DOI: 10.1016/j.bmcl.2010.01.094
Abstract

Discovery efforts were focused on identifying a non-nucleoside Antiviral for treating infections caused by human cytomegalovirus (HCMV) with equal or better potency and diminished toxicity compared to current therapeutics. This Letter describes the HCMV DNA Polymerase inhibition and in vitro Antiviral activity of various 2-aryl-2-hydroxy ethylamine substituted 1H,7H-pyrido[1,2,3-de]quinoxaline-6-carboxamides.